HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes

被引:27
作者
Gjertsen, MK [1 ]
Sæterdal, I [1 ]
Sæboe-Larssen, S [1 ]
Gaudernack, G [1 ]
机构
[1] Univ Oslo, Norwegian Radium Hosp, Dept Immunol, Sect Immunotherapy, N-0310 Oslo, Norway
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2003年 / 81卷 / 01期
关键词
cytotoxic T lymphocytes; p2l ras; peptide vaccination; pancreatic cancer; granulocyte-macrophage colony-stimulating factor;
D O I
10.1007/s00109-002-0390-y
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cytotoxic T-lymphocytes are one of the most important elements of the antitumor defense. Stimulation of cytotoxic T-lymphocytes outgrowth after immunization with mutant ras peptides is a desired goal since these cells may kill tumor cells in vivo. In this study we tested responding peripheral mononuclear cells from a patient with pancreatic adenocarcinoma who had received intradermal peptide vaccination with a mixture of 17-mer mutant ras peptides and granulocyte-macrophage colony-stimulating factor as an adjuvant. Responding peripheral T-cells were cloned by limiting dilution and several CD8(+) cytotoxic T-lymphocytes, specific for the K-RAS 12-Cys mutation were obtained. By using a panel of nonamer peptides containing the 12-Cys mutation and covering position 4-21 in the ras molecule, the 9-mer peptide which was actually recognized by the cytotoxic T-lymphocytes could be idenfified. HLA-A*0302 could be identified as the antigen-presenting molecule, and the amino acid sequence of the T-cell epitope carries the previously identified HLA-A*0302 binding motif. The nonamer peptide was contained within the vaccine peptide originally used for intradermal immunization of the patient. The cytotoxic T-lymphocytes were capable of killing target cells expressin HLA-A*0302 that coexpressed the K-RAS 12-Cys mutation after transfection. These data demonstrate that the peptide used for vaccination (17-mer) is processed and presented in vivo, and that generation of cytotoxic T-lymphocytes by vaccination with T-helper epitopes may be important for further development of specific immunotherapy of cancer patients.
引用
收藏
页码:43 / 50
页数:8
相关论文
共 40 条
[11]   MEMORY T-CELLS OF A PATIENT WITH FOLLICULAR THYROID-CARCINOMA RECOGNIZE PEPTIDES DERIVED FROM MUTATED P21 RAS (GLN-]LEU61) [J].
GEDDEDAHL, T ;
SPURKLAND, A ;
ERIKSEN, JA ;
THORSBY, E ;
GAUDERNACK, G .
INTERNATIONAL IMMUNOLOGY, 1992, 4 (11) :1331-1337
[12]   VACCINATION WITH MUTANT RAS PEPTIDES AND INDUCTION OF T-CELL RESPONSIVENESS IN PANCREATIC-CARCINOMA PATIENTS CARRYING THE CORRESPONDING RAS MUTATION [J].
GJERTSEN, MK ;
BAKKA, A ;
BREIVIK, J ;
SAETERDAL, I ;
SOLHEIM, BG ;
SOREIDE, O ;
THORSBY, E ;
GAUDERNACK, G .
LANCET, 1995, 346 (8987) :1399-1400
[13]  
Gjertsen MK, 1997, INT J CANCER, V72, P784, DOI 10.1002/(SICI)1097-0215(19970904)72:5<784::AID-IJC14>3.3.CO
[14]  
2-G
[15]   Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant:: Clinical and immunological responses in patients with pancreatic adenocarcinoma [J].
Gjertsen, MK ;
Buanes, T ;
Rosseland, AR ;
Bakka, A ;
Gladhaug, I ;
Soreide, O ;
Eriksen, JA ;
Moller, M ;
Baksaas, I ;
Lothe, RA ;
Sæterdal, I ;
Gaudernack, G .
INTERNATIONAL JOURNAL OF CANCER, 2001, 92 (03) :441-450
[16]   HUMAN LYMPHOCYTES-T RECOGNIZE A PEPTIDE OF SINGLE POINT-MUTATED, ONCOGENIC RAS PROTEINS [J].
JUNG, S ;
SCHLUESENER, HJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (01) :273-276
[17]  
Kawakami Y, 1998, J IMMUNOL, V161, P6985
[18]   The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors [J].
Kawashima, I ;
Hudson, SJ ;
Tsai, V ;
Southwood, S ;
Takesako, K ;
Appella, E ;
Sette, A ;
Celis, E .
HUMAN IMMUNOLOGY, 1998, 59 (01) :1-14
[19]   A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors [J].
Khleif, SN ;
Abrams, SI ;
Hamilton, JM ;
Bergmann-Leitner, E ;
Chen, A ;
Bastian, A ;
Bernstein, S ;
Chung, YM ;
Allegra, CJ ;
Schlom, J .
JOURNAL OF IMMUNOTHERAPY, 1999, 22 (02) :155-165
[20]   Tumor escape from immune recognition - Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen [J].
Maeurer, MJ ;
Gollin, SM ;
Martin, D ;
Swaney, W ;
Bryant, J ;
Castelli, C ;
Robbins, P ;
Parmiani, G ;
Storkus, WJ ;
Lotze, MT .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (07) :1633-1641